Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092143 · ClinicalTrials.gov registry record · Phase 2
BI 671800 ED in Steroid-naive Asthmatic Patients
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 389
- Enrollment target
NCT01092143 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 389 participants.
The verdict
NCT01092143, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 389 participants
- Enrollment target
Study Summary
This is a 6 week study to investigate the effectiveness and safety of BI 671800 ED in patients with asthma who do not take inhaled corticosteroids.
Interventions
- DRUG Fluticasone propionate
- DRUG BI 671800
- DRUG Fluticasone propionate placebo
- DRUG BI 671800 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2010-03-18 |
| Est. Completion | 2011-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01092143
The ClinicalTrials.gov registry entry for NCT01092143 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluticasone propionate is the first listed.
NCT01092143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01092143 about?
NCT01092143 is a clinical study titled "BI 671800 ED in Steroid-naive Asthmatic Patients". This is a 6 week study to investigate the effectiveness and safety of BI 671800 ED in patients with asthma who do not take inhaled corticosteroids.
What is the current status of trial NCT01092143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 389 participants. The study started on 2010-03-18. Estimated completion is 2011-03-26.
What interventions are being tested in trial NCT01092143?
The interventions under investigation include: Fluticasone propionate (DRUG), BI 671800 (DRUG), Fluticasone propionate placebo (DRUG), BI 671800 Placebo (DRUG).
Who is sponsoring clinical trial NCT01092143?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.